A detailed history of Franklin Resources Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Franklin Resources Inc holds 664,336 shares of NBIX stock, worth $81.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
664,336
Previous 808,450 17.83%
Holding current value
$81.9 Million
Previous $111 Million 31.28%
% of portfolio
0.02%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$114.58 - $153.15 $16.5 Million - $22.1 Million
-144,114 Reduced 17.83%
664,336 $76.5 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $1.91 Million - $2.09 Million
14,625 Added 1.84%
808,450 $111 Million
Q1 2024

May 13, 2024

BUY
$130.4 - $143.74 $2.81 Million - $3.09 Million
21,515 Added 2.79%
793,825 $109 Million
Q4 2023

Feb 09, 2024

BUY
$106.07 - $132.76 $649,572 - $813,022
6,124 Added 0.8%
772,310 $102 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $3.57 Million - $4.44 Million
37,936 Added 5.21%
766,186 $86.2 Million
Q2 2023

Aug 11, 2023

BUY
$89.53 - $104.87 $1.59 Million - $1.87 Million
17,806 Added 2.51%
728,250 $68.7 Million
Q1 2023

May 12, 2023

BUY
$94.11 - $123.02 $1.57 Million - $2.05 Million
16,672 Added 2.4%
710,444 $71.9 Million
Q4 2022

Feb 10, 2023

SELL
$106.72 - $127.06 $38.3 Million - $45.5 Million
-358,463 Reduced 34.07%
693,772 $82.9 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $11.9 Million - $13.9 Million
-128,820 Reduced 10.91%
1,052,235 $112 Million
Q2 2022

Aug 11, 2022

BUY
$75.79 - $100.07 $4.95 Million - $6.54 Million
65,313 Added 5.85%
1,181,055 $115 Million
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $11 Million - $14.4 Million
151,921 Added 15.76%
1,115,742 $105 Million
Q4 2021

Feb 11, 2022

SELL
$79.65 - $106.22 $16,168 - $21,562
-203 Reduced 0.02%
963,821 $82.1 Million
Q3 2021

Nov 12, 2021

BUY
$86.18 - $99.03 $128,408 - $147,554
1,490 Added 0.15%
964,024 $92.5 Million
Q2 2021

Aug 13, 2021

BUY
$89.43 - $102.27 $5.16 Million - $5.9 Million
57,680 Added 6.37%
962,534 $93.7 Million
Q1 2021

May 13, 2021

BUY
$87.57 - $119.4 $874,298 - $1.19 Million
9,984 Added 1.12%
904,854 $88 Million
Q4 2020

Feb 10, 2021

SELL
$86.91 - $108.33 $55.2 Million - $68.8 Million
-635,290 Reduced 41.52%
894,870 $85.8 Million
Q3 2020

Nov 12, 2020

BUY
$96.16 - $135.15 $7.49 Million - $10.5 Million
77,878 Added 5.36%
1,530,160 $147 Million
Q2 2020

Aug 13, 2020

SELL
$85.09 - $130.36 $19.2 Million - $29.4 Million
-225,399 Reduced 13.44%
1,452,282 $189 Million
Q1 2020

May 13, 2020

SELL
$75.11 - $113.76 $23 Million - $34.8 Million
-305,818 Reduced 15.42%
1,677,681 $145 Million
Q4 2019

Feb 12, 2020

BUY
$86.8 - $118.57 $10.7 Million - $14.6 Million
122,980 Added 6.61%
1,983,499 $213 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $17.5 Million - $21.2 Million
208,688 Added 12.63%
1,860,519 $168 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $28 Million - $35.3 Million
-387,307 Reduced 18.99%
1,651,831 $139 Million
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $984,202 - $1.3 Million
14,200 Added 0.7%
2,039,138 $180 Million
Q4 2018

Feb 12, 2019

BUY
$68.32 - $124.36 $12.6 Million - $22.9 Million
184,415 Added 10.02%
2,024,938 $145 Million
Q3 2018

Nov 13, 2018

BUY
$98.88 - $125.85 $1.5 Million - $1.9 Million
15,137 Added 0.83%
1,840,523 $226 Million
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $40 Million - $56.3 Million
-531,200 Reduced 22.54%
1,825,386 $179 Million
Q1 2018

May 10, 2018

SELL
$75.88 - $92.43 $54.2 Million - $66.1 Million
-714,800 Reduced 23.27%
2,356,586 $195 Million
Q4 2017

Feb 14, 2018

SELL
$58.53 - $77.59 $11.4 Million - $15.1 Million
-194,229 Reduced 5.95%
3,071,386 $238 Million
Q3 2017

Nov 13, 2017

BUY
$47.97 - $61.28 $157 Million - $200 Million
3,265,615
3,265,615 $200 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.